Business
Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine
Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of
About this update from Denali Therapeutics Inc.
[{"type":"text","content":"Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with DNL310 (ETV:IDS), the first product candidate enabled by the transport vehicle technology, are expected in Hunter syndrome patients by late 2020Denali’s EngageHunter.com website provides patients, caregivers and others information on Denali’s investigational studies as well as developments in Hunter syndrome and Denali’s approach to treating the disease SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today announced publication of two papers in Science Translational Medicine (“STM”). The papers describe the company’s Transport Vehicle (“TV”) technology, illustrate its ability to successfully deliver therapeutic proteins to the brain at levels sufficient for robust effects, and demonstrate the normalization of biomarkers in a disease model of Hunter syndrome. The company also provided an update on product candidate DNL310, its most advanced TV platform-enabled molecule.\n “Engineering our medicines for brain delivery is one of our three scientific principles and is a core part of our strategy to defeat degeneration,” said Ryan Watts, Ph.D., CEO. “We are excited to have two papers published in STM today. Taken together, these papers demonstrate the potential of our protein engineering approach, describe in vivo proof-of-concept studies for the TV platform in mice and non-human primates, and illustrate the application of the TV technology to enzymes for the treatment of lysosomal storage diseases. The peer-review and publication of these papers are important independent examinations of our platform and approach.” The BBB is essential in maintaining the brain’s microenvironment and protecting it from harmful substances and pathogens circulating in the bloodstream. Historically, the BBB has posed significant challenges to drug development for central nervous system (“CNS”) diseases by preventing most drugs from reaching the brain in therapeutically relevant concentrations. Denali’s TV platform is a proprietary technology designed to effectively de...